TransCode Therapeutics is a biotechnology business based in the US. TransCode Therapeutics shares (RNAZ) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.51 – an increase of 34.79% over the previous week. TransCode Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.51 |
|---|---|
| 52-week range | $0.22 - $66.33 |
| 50-day moving average | $1.16 |
| 200-day moving average | $8.69 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-47.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5122 from 2025-05-02
| 1 week (2025-04-25) | 34.79% |
|---|---|
| 1 month (2025-04-04) | 11.79% |
| 3 months (2025-02-04) | -91.69% |
| 6 months (2024-11-04) | -0.54% |
| 1 year (2024-05-03) | -37.54% |
|---|---|
| 2 years (2023-05-04) | -99.99% |
| 3 years (2022-05-04) | 75504 |
| 5 years (2020-04-30) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -157.06% |
| Return on equity TTM | -490.03% |
| Profit margin | 0% |
| Book value | $-1.96 |
| Market Capitalization | $12 million |
TTM: trailing 12 months
We're not expecting TransCode Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
TransCode Therapeutics's shares were split on a 1:33 basis on 3 December 2024 . So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TransCode Therapeutics shares – just the quantity. However, indirectly, the new 3200% higher share price could have impacted the market appetite for TransCode Therapeutics shares which in turn could have impacted TransCode Therapeutics's share price.
Over the last 12 months, TransCode Therapeutics's shares have ranged in value from as little as $0.2196 up to $66.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TransCode Therapeutics's is 1.519. This would suggest that TransCode Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put TransCode Therapeutics's beta into context you can compare it against those of similar companies.
TransCode Therapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .